Report Detail
Global (United States, European Union and China) Hemophilia Drugs Market Research Report 2019-2025
- RnM3669398 |
- 14 August, 2019 |
- Global |
- 117 Pages |
- QYResearch |
- Pharma & Healthcare
The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab’ by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate’ for type A and ‘Aprolix’ for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.
With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth over the forecast period.
The Americas led the global hemophilia drugs market in 2017 and is expected to continue its dominance until the end of 2023. The Americas have the highest revenue share in the global market with the US contributing to the majority of this revenue. Several countries in the region have introduced health care reforms which are having a positive impact on the market growth. Moreover, healthcare reforms in the US have also helped reduce the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms are likely to have a positive impact on healthcare insurance and also reduce hospital stay and overall medical expenses, which will boost this market’s growth in the region.
In 2019, the market size of Hemophilia Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hemophilia Drugs.
This report studies the global market size of Hemophilia Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Hemophilia Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Baxalta
Bayer
CSL Behring
Pfizer
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F. Hoffmann-La Roche
Grifols
Octapharma
Sangamo Biosciences
Spark Therapeutics
Swedish Orphan Biovitrum
Market Segment by Product Type
Hemophilia A
Inhibitors
Hemophilia B
Von Willebrand Disease
Market Segment by Application
Recombinant Therapies
Plasma-Derived Therapies
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Hemophilia Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Hemophilia Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Hemophilia Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Hemophilia Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Hemophilia A
- 1.3.3 Inhibitors
- 1.3.4 Hemophilia B
- 1.3.5 Von Willebrand Disease
- 1.4 Market Segment by Application
- 1.4.1 Global Hemophilia Drugs Market Share by Application (2019-2025)
- 1.4.2 Recombinant Therapies
- 1.4.3 Plasma-Derived Therapies
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Hemophilia Drugs Market Size
- 2.1.1 Global Hemophilia Drugs Revenue 2014-2025
- 2.1.2 Global Hemophilia Drugs Sales 2014-2025
- 2.2 Hemophilia Drugs Growth Rate by Regions
- 2.2.1 Global Hemophilia Drugs Sales by Regions 2014-2019
- 2.2.2 Global Hemophilia Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Hemophilia Drugs Sales by Manufacturers
- 3.1.1 Hemophilia Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Hemophilia Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Hemophilia Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Hemophilia Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Hemophilia Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Hemophilia Drugs Price by Manufacturers
- 3.4 Key Manufacturers Hemophilia Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Hemophilia Drugs Market
- 3.6 Key Manufacturers Hemophilia Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Hemophilia A Sales and Revenue (2014-2019)
- 4.1.2 Inhibitors Sales and Revenue (2014-2019)
- 4.1.3 Hemophilia B Sales and Revenue (2014-2019)
- 4.1.4 Von Willebrand Disease Sales and Revenue (2014-2019)
- 4.2 Global Hemophilia Drugs Sales Market Share by Type
- 4.3 Global Hemophilia Drugs Revenue Market Share by Type
- 4.4 Hemophilia Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Hemophilia Drugs Sales by Application
6 United States
- 6.1 United States Hemophilia Drugs Breakdown Data by Company
- 6.2 United States Hemophilia Drugs Breakdown Data by Type
- 6.3 United States Hemophilia Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Hemophilia Drugs Breakdown Data by Company
- 7.2 European Union Hemophilia Drugs Breakdown Data by Type
- 7.3 European Union Hemophilia Drugs Breakdown Data by Application
8 China
- 8.1 China Hemophilia Drugs Breakdown Data by Company
- 8.2 China Hemophilia Drugs Breakdown Data by Type
- 8.3 China Hemophilia Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Hemophilia Drugs Breakdown Data by Company
- 9.2 Rest of World Hemophilia Drugs Breakdown Data by Type
- 9.3 Rest of World Hemophilia Drugs Breakdown Data by Application
- 9.4 Rest of World Hemophilia Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Hemophilia Drugs Sales by Countries
- 9.4.2 Rest of World Hemophilia Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Baxalta
- 10.1.1 Baxalta Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Hemophilia Drugs
- 10.1.4 Hemophilia Drugs Product Introduction
- 10.1.5 Baxalta Recent Development
- 10.2 Bayer
- 10.2.1 Bayer Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Hemophilia Drugs
- 10.2.4 Hemophilia Drugs Product Introduction
- 10.2.5 Bayer Recent Development
- 10.3 CSL Behring
- 10.3.1 CSL Behring Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Hemophilia Drugs
- 10.3.4 Hemophilia Drugs Product Introduction
- 10.3.5 CSL Behring Recent Development
- 10.4 Pfizer
- 10.4.1 Pfizer Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Hemophilia Drugs
- 10.4.4 Hemophilia Drugs Product Introduction
- 10.4.5 Pfizer Recent Development
- 10.5 Alnylam Pharmaceuticals
- 10.5.1 Alnylam Pharmaceuticals Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Hemophilia Drugs
- 10.5.4 Hemophilia Drugs Product Introduction
- 10.5.5 Alnylam Pharmaceuticals Recent Development
- 10.6 BioMarin
- 10.6.1 BioMarin Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Hemophilia Drugs
- 10.6.4 Hemophilia Drugs Product Introduction
- 10.6.5 BioMarin Recent Development
- 10.7 Catalyst Biosciences
- 10.7.1 Catalyst Biosciences Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Hemophilia Drugs
- 10.7.4 Hemophilia Drugs Product Introduction
- 10.7.5 Catalyst Biosciences Recent Development
- 10.8 Dimension Therapeutics
- 10.8.1 Dimension Therapeutics Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Hemophilia Drugs
- 10.8.4 Hemophilia Drugs Product Introduction
- 10.8.5 Dimension Therapeutics Recent Development
- 10.9 F. Hoffmann-La Roche
- 10.9.1 F. Hoffmann-La Roche Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Hemophilia Drugs
- 10.9.4 Hemophilia Drugs Product Introduction
- 10.9.5 F. Hoffmann-La Roche Recent Development
- 10.10 Grifols
- 10.10.1 Grifols Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Hemophilia Drugs
- 10.10.4 Hemophilia Drugs Product Introduction
- 10.10.5 Grifols Recent Development
- 10.11 Octapharma
- 10.12 Sangamo Biosciences
- 10.13 Spark Therapeutics
- 10.14 Swedish Orphan Biovitrum
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Hemophilia Drugs Sales Channels
- 11.2.2 Hemophilia Drugs Distributors
- 11.3 Hemophilia Drugs Customers
12 Market Forecast
- 12.1 Global Hemophilia Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Hemophilia Drugs Sales Forecast by Type
- 12.3 Global Hemophilia Drugs Sales Forecast by Application
- 12.4 Hemophilia Drugs Forecast by Regions
- 12.4.1 Global Hemophilia Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Hemophilia Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Hemophilia Drugs. Industry analysis & Market Report on Hemophilia Drugs is a syndicated market report, published as Global (United States, European Union and China) Hemophilia Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Hemophilia Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
